Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer (GeparSixto)
This study is ongoing, but not recruiting participants.
Sponsor:
German Breast Group
Collaborators:
TEVA
Roche Pharma AG
GlaxoSmithKline
Information provided by (Responsible Party):
German Breast Group
ClinicalTrials.gov Identifier:
NCT01426880
First received: August 17, 2011
Last updated: May 22, 2013
Last verified: May 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is ongoing, but not recruiting participants. |
|---|---|
| Estimated Study Completion Date: | July 2013 |
| Primary Completion Date: | May 2013 (Final data collection date for primary outcome measure) |